Sales of pharmaceutical drugs Thailand 2021, by type

In 2021, generic drug sales in Thailand amounted to around 94 billion Thai baht. Generic drugs accounted for the largest share of drug sales in Thailand since 2017, followed by patented drugs and over-the-counter drugs. Since the global pandamic, more focus has been given to the pharmaceutical sector, as is the case in Thailand. Strengths and weaknesses of the Thai pharmaceutical marketDespite the use of compulsory licensing, the pharmaceutical sector in Thailand still faces the challenge of low intellectual property protection, resulting in a high level of counterfeit drugs. However, the Ministry of Public Health has started to enforce stricter drug laws and regulations. This would have an impact on the number of issued selling licenses for modern medicine. Regardless of the challenges, Thailand’s established universal healthcare system and strong private hospital growth contribute to the development of the pharmaceutical market.The future of pharmaceuticals in Thailand Given the current situation of the coronavirus (COVID-19) pandemic, more consumers have stocked up on over-the-counter medication and pharmaceutical drugs such as paracetamol. This increase in demand was probably a factor in the short term rise in the number of newly established pharmaceutical businesses at the beginning of 2020. Furthermore, pharmaceutical sales as a share of GDP were forecasted to increase in the future as well. This has pushed the sector to engage in more research and development, indicating more government attention in pharmaceuticals and thus signaling higher investment in the future.

于2021年，泰国仿制药的销售总额约为940亿泰铢。自2017年以来，仿制药已成为泰国药品销售的最大份额，紧随其后的是专利药品和非处方药品。自全球大流行病以来，医药行业受到了更多的关注，泰国亦然。尽管泰国采用了强制许可制度，但其医药行业仍面临知识产权保护不足的挑战，导致假冒药品水平较高。然而，公共卫生部已经开始执行更严格的药品法律法规，这将影响现代药品销售许可证的发放数量。尽管面临挑战，泰国成熟的全民医疗保健体系和私营医院的强劲增长为医药市场的发展做出了贡献。《泰国医药行业的未来》鉴于当前冠状病毒（COVID-19）大流行的形势，更多消费者囤积了非处方药物和如对乙酰氨基酚等药品。这种需求的增加可能是2020年初新成立医药企业数量短期上升的因素之一。此外，预计医药销售额占GDP的比例将在未来增加，这促使该行业加大研发投入，表明政府对医药行业的关注增加，从而预示着未来将有更高的投资。